Term
|
Definition
Any chemical substance other than those required for normal sustenance which produces a biological effect |
|
|
Term
|
Definition
The study of the manner in which the function of living systems is affected by chemical substances |
|
|
Term
|
Definition
Agents naturally produced in animal cells, microorganisms, or the body itself |
|
|
Term
SCHEDULES OF CONTROLLED DRUGS SCHEDULE I |
|
Definition
- All nonresearch use is foribidden
- Hallucinogens
- LSD, MDA, STP, DMT, mescaline, peyote, bufoteneine, ibojaine, psilocybin,
- Marijuana, tetrahydrocannabinols
|
|
|
Term
SCHEDULES OF CONTROLLED DRUGS SCHEDULE II |
|
Definition
- Prescriptions must be filled at pharmacy within 24 hours
- Can only be written for up to one month - NO REFILLS
- Narcotics
- Opium, Opium alkaloids and derivatives
- Stimulants
- Cocaine, Amphetamine (and derivatives), Methylphenidate (Ritalin)
- Depressants
|
|
|
Term
SCHEDULES OF CONTROLLED DRUGS SCHEDULE III |
|
Definition
- Prescriptions must be rewritten after 6 months
- Narcotics (maximum amounts exist)
- Codeine, dihydrocodeine, opium
- Depressants
- barbiturates mixed with uncontrolled drugs
- Stimulants
- Benzphetamine
- Chlorphentermine
- Diethylpropion
- Maxindol
|
|
|
Term
SCHEDULES OF CONTROLLED DRUGS SCHEDULE IV |
|
Definition
- Prescriptions must be rewritten after 6 months - differs from sched. III in penalties for illegal possession.
- Narcotics
- Stimulants
- Depressants
|
|
|
Term
NURSING IMPLICATIONS Drug Regulation |
|
Definition
- The pt has final control over drug use - gives or withholds consent and determines compliance.
- It is our responsibility as nurses to inform pt of options so they can make an educated decision.
- Nurses must be familiar with regulations affecting drug use
|
|
|
Term
SCHEDULES OF CONTROLLED DRUGS SCHEDULE V |
|
Definition
- May be dispensed without prescription unless additional state regulations apply.
- Narcotics - no more than 2.5 mg and no less than 0.025 mg of atropine per dosage unit.
- Codeines and ethylmorphine
|
|
|
Term
|
Definition
- 5 categories exist which indicate potential of a drug for causing birth defects
- Categories are labeled A, B, C, D, X (in order of increasing risk)
|
|
|
Term
FDA PREGNANCY CATEGORIES CATEGORY A |
|
Definition
- Adequate studies in pregnant women have not demonstrated risk to the fetus
- Vitamins, Minerals
|
|
|
Term
FDA PREGNANCY CATEGORIES CATEGORY B |
|
Definition
- Animal studies have not demonstrated a risk to the fetus.
- No adequate studies in pregnant women
- Tylenol, insulin, amoxicillin..
|
|
|
Term
FDA PREGNANCY CATEGORIES CATEGORY C |
|
Definition
- Animal studies have shown an adverse effect on the fetus
- No adequate studies in humans
- Benefits from use of the drug may outweigh potential risks
- Ofloxacin, Bactrim DC, Diflucan
|
|
|
Term
FDA PREGNANCY CATEGORIES CATEGORY D |
|
Definition
- Evidence of human fetal risk
- In life threatening cases may be used
- doxycycline
|
|
|
Term
FDA PREGNANCY CATEGORIES CATEGORY X |
|
Definition
- Studies in animals or humans demonstrated fetal abnormalities or adverse reaction.
- The risk of use in pregnant women clearly outweighs any possible benefit
- Accutane
|
|
|
Term
|
Definition
- No false or misleading statements
- Dosage and frequency must be clearly stated
- Name, address, and lot # of manufacturer
- Accurate statement of contents
- Warning if habit forming
- Quantity, kind, and preparation of specific ingredients
- Directions for use and contraindications
|
|
|
Term
|
Definition
- May take 6-12 years for development and testing
- Only 1/5000 compounds emerge as a new product
|
|
|
Term
DRUG DEVELOPMENT
STAGES OF DRUG DEVELOPMENT |
|
Definition
- Preclinical testing
- investigation, extensive lab testing
- may take 1-5 years
- Clinical testing
- Occurs in 4 phases
- May take 2-10 years to complete
- first 3 phases are done before drug is marketed
|
|
|
Term
DRUG DEVELOPMENT PHASE I of CLINICAL TESTING |
|
Definition
- Normal, healthy volunteers
- Takes about 1 year
- Goals: evaluations of drug metabolism & determination of effects on humans
|
|
|
Term
DRUG DEVELOPMENT PHASE II of CLINICAL TESTING |
|
Definition
- Volunteers with the disease
- Lasts about 2 years
- Goals: Therapeutic effects & Dose range
|
|
|
Term
DRUG DEVELOPMENT PHASE III of CLINICAL TESTING |
|
Definition
- Random, Single, and Double Blind testing
- Takes about 3 years
- Goals: Safety & Effectiveness
*Upon completion of this phase a New Drug Application may be submitted to the FDA for approval* |
|
|
Term
DRUG DEVELOPMENT PHASE IV of CLINICAL TESTING |
|
Definition
- Postmarketing Surveillance
- Drug released for general use - permitting observation of its effects in a large population
- If FDA discovers serious problems it mandates drug be withdrawn from the market
|
|
|
Term
SIX PRINCIPLES OF DRUG ADMINISTRATION |
|
Definition
- RIGHT DRUG - preparer is one held liable
- RIGHT DOSE - nurses are last line in defense against errors
- RIGHT ROUTE
- RIGHT TIME - is pt taking multiple medication? Does pt have full/empty stomach? Can meds be taken concurrently?
- RIGHT PATIENT
- RIGHT DOCUMENTATION
|
|
|
Term
|
Definition
- Know generic names instead of Trade names
- generic name will always be uncapitalized, Trade names will be capitalized.
- Trade names are different in different countries
- Pharmacist may substitute for generic unless DAW (dispense as written) is noted.
|
|
|
Term
|
Definition
- Should always include the following:
- PT's name
- Date
- Name of drug
- Dose of drug
- Route of administration
- Frequency of administration
- Duration of the therapy
- Quantity to be dispensed
Ex. PCN 500mg PO TID x10
'500 milligrams of penicillin by mouth 3 times/day for 10 days' |
|
|
Term
|
Definition
- Standing order with termination
- PCN 500mg PO QID x 10 days
- Standing order without termination
- PRN (as needed)
- Acetaminophn 500mg PO q 4-6 hrs PRN
- Single-dose orders
- Stat order
- Protocol orders
|
|
|
Term
NOMENCLATURE GENERIC NAME |
|
Definition
- Provided by the USAN Council (United States Adopted Names)
- Used in all countries by any manufacturers
- NOT capitalized
|
|
|
Term
|
Definition
- Patent name given by manufacturer
- The name under which the drug is marketed
- Trade names are approved by the FDA
- Copyrighted symbol is displayed in upper righthand of the name
|
|
|
Term
NOMENCLATURE GENERIC VS. BRAND NAME PRODUCTS |
|
Definition
- NO differences exist between the two - all equivalent products contain the same dose of the same drug.
- The only difference is in the inert ingredients
|
|
|
Term
DRUG CONSTITUENTS MAJOR CATEGORIES OF ACTIVE INGREDIENTS |
|
Definition
- Alkaloids
- Glycosides
- Oils
- Gums
- Resins
|
|
|
Term
SOLID DOSAGE FORMS CAPSULES |
|
Definition
- Small, cylindrical gelatin containers, holding a dry powder or liquid medicinal agent.
- Convenient way of administering drugs with unpleasant odor or taste
- Can be used as a delayed-action dosage form
|
|
|
Term
SOLID DOSAGE FORMS TABLETS |
|
Definition
- Dried, powdered drugs compressed into small disks
- May have special coating aloweing the tablet to dissolve slowl; releasing the medicinal agent over a prolonged time.
|
|
|
Term
SOLID DOSAGE FORMS CREAMS |
|
Definition
- Solid emulsions containing agents for external application
|
|
|
Term
SOLID DOSAGE FORMS EXTRACTS |
|
Definition
- Concentrate, solid preparations of drugs obtained by dissolving the crude drug in alcohol or water; the solution is then allowed to evaporate
- Sedimen - extract
|
|
|
Term
SOLID DOSAGE FORMS LOZENGES |
|
Definition
Flat discs containing a medical agent in a flavored base |
|
|
Term
SOLID DOSAGE FORMS OINTMENTS |
|
Definition
Semisolid preparations of medicinal substances in an oily base; such as lanolin or petroleum |
|
|
Term
SOLID DOSAGE FORMS POWDERS |
|
Definition
Ground drugs into a fine powder & used in this form |
|
|
Term
SOLID DOSAGE FORMS SUPPOSITORIES |
|
Definition
Mixture of drugs with a firm base, such as cocoa butter, melting at body temperature |
|
|
Term
LIQUID DOSAGE FORMS AMPULES & VIALS |
|
Definition
- Glass containers with powdered or liquid drugs
- Used for drugs given by injection
- Ampules: sealed glass containers with one dose of the drug
- Vials: glass container w/ rubber stopper containing a number of doses of the drug
|
|
|
Term
LIQUID DOSAGE FORMS ELIXIRS |
|
Definition
Palatable preparations of drugs made up with alcohol, sugar, and some aromatic substance |
|
|
Term
LIQUID DOSAGE FORMS EMULSIONS |
|
Definition
Suspensions of oils or fats in water maintained by emulsifying agents such as Sodium Lauryl Sulfate |
|
|
Term
|
Definition
Aqueous suspensions of insoluble drugs in hydrated form |
|
|
Term
LIQUID DOSAGE FORMS LINIMENTS |
|
Definition
Mixtures of drugs with soap, oil, water, or alcohol to be used for external application only |
|
|
Term
LIQUID DOSAGE FORMS LOTIONS |
|
Definition
Aqueous preparations that contain suspended matter |
|
|
Term
LIQUID DOSAGE FORMS MAGMA |
|
Definition
Bulky suspensions, in water, of drugs that are insoluble; they look like milk or cream |
|
|
Term
LIQUID DOSAGE FORMS PREFILLED SYRINGES |
|
Definition
Contain a prepared doseage ready for immediate use |
|
|
Term
LIQUID DOSAGE FORMS SPIRITS |
|
Definition
Preparations of volatile (evaporating into vapor) substances dissolved in alcohol eg, spirit of peppermint |
|
|
Term
LIQUID DOSAGE FORMS SUSPENSIONS |
|
Definition
Solid, insoluble particles dispensed in a liquid *all must be shaken before use* |
|
|
Term
LIQUID DOSAGE FORMS SYRUPS |
|
Definition
Contain medicinal agents dissolved in sugar and water solution *particularly effective for masking taste of drug* |
|
|
Term
LIQUID DOSAGE FORMS TINCTURES |
|
Definition
Diluted alcoholic extracts of drugs Vary in strength from 10% - 20% |
|
|
Term
PROPERTIES OF AN IDEAL DRUG (ALTHOUGH THERE'S NO SUCH THING...) |
|
Definition
- EFFECTIVENESS
- Must elicit response for which it is given
- SAFETY
- Cannot produce harmful effects
- SELECTIVITY
- Elicits only the response for which it is given (no side effects)
|
|
|
Term
FACTORS DETERMINING INTENSITY OF DRUG RESPONSE |
|
Definition
- Administration
- dosage size & route, timing
- Pharmacokinetics
- how the body interacts, what is happening while the drug courses throughout
- Pharmacodynamics
- how the drugs exert their action, what the drug is doing
|
|
|
Term
|
Definition
The branch of pharmacology concerned with mechanisms of drug action & relationships between drug concentration and responses in the body - DRUGS MAY ACT EITHER TO CHANGE THE ENVIRONMENT OF THE CELL OF TO ALTER THE RATE OF CELL FUNCTIONS, THEY DO NOT CREATE NEW FUNCTIONS!!!!
|
|
|
Term
FOUR PRIMARY RECEPTOR FAMILIES |
|
Definition
- Cell Membrane-Embedded Enzymes
- Ligand-Gated Ion Channels
- G Protein-Coupled Receptor Systems
- Transcription Factors
|
|
|
Term
|
Definition
Property of the receptor that lets it discriminate among similar compounds |
|
|
Term
|
Definition
Effects of the drug; may be nonselective or relatively selective *Selectivity does not guarantee safety |
|
|
Term
|
Definition
- Degree or strength of attraction between a drug and its receptor
- Better affinity - less dosing needed to produce a desired response
- Affinity is reflected in the potency of the drug
- Drugs with high affinity have high relative potency
|
|
|
Term
|
Definition
The ability of a drug to transduce a drug-receptor binding event into a biologic response Reflected in the drug's maximal efficacy - largest effect that it can produce Drugs with high intrinsic activity have maximal efficacy |
|
|
Term
|
Definition
*Mimics to create an action - WILL have intrinsic activity and affinity* |
|
|
Term
|
Definition
*Mimics to block the action - will NOT have intrinsic activity Can be competitive or noncompetitive |
|
|
Term
|
Definition
Binds reversibly to receptors |
|
|
Term
NONCOMPETITIVE ANTAGONIST |
|
Definition
Bind irreversibly to receptors so total number of receptors available to agonists is reduced |
|
|
Term
REGULATION OF RECEPTOR SENSITIVITY |
|
Definition
- Continuous exposure to agonists can result in receptor desensitization
- When this occurs, cell is said to be desensitized or refractory
- Has undergone down-regulation
- Continuous exposure to antagonists can result in receptor hypersensitivity (up-regulation)
|
|
|
Term
|
Definition
An increased potency allows a therapeutic effect at a lower dose Drugs with high affinity are generally considered potent *unrelated to drug dose* |
|
|
Term
|
Definition
Magnitude of maximal response that can be produced from a particular drug |
|
|
Term
|
Definition
Used as a measure of a drug's safety TI = LD50 / TD50 The TI indicates the ratio between the lethal dose and the therapeutic dose (taken as averages in 50% of the pop.) Large TI - drug is relatively safe Small TI - relatively unsafe |
|
|
Term
DRUG RESPONSES SIDE EFFECTS |
|
Definition
- Expected, unavoidable reactions
- Can be minor, cosmetic, or serious
- Only serious are life threatening
|
|
|
Term
DRUG RESPONSES ADVERSE DRUG REACTIONS |
|
Definition
Any unintended and undesired effect occurring at normal dose |
|
|
Term
|
Definition
Adverse reactions caused by excessive dosing |
|
|
Term
|
Definition
- Pharmacodynamic Tolerance
- associated with long term administration of drug
- Metabolic Tolerance
- Tolerance resulting from accelerated metabolism
- Tachyphylaxis
- Tolerance defined as a reduction in drug responsiveness brought by repeated dosing over a short time
|
|
|
Term
DRUG RESPONSES DRUG DEPENDENCE |
|
Definition
- Psychological dependence
- An emotional drive to continue taking a drug in order to maintain an optimal sense of well-being
- Physiologic dependence
- Alteration in physical state produced by repeated administration of a drug
|
|
|
Term
DRUG RESPONSES IDIOSYNCRATIC REACTION |
|
Definition
An unexpected or exaggerated effect to a typical dose *resulting from genetic predisposition* |
|
|
Term
FOUR BASIC PROCESSES OF PHARMACOKINETICS |
|
Definition
- Absorption
- drug movement from administration site to blood
- Distribution
- transport of medicine to target tissues
- Metabolism / Biotransformation
- enzymatically mediated alteration of drug structure
- Excretion
- elimination of medication & metabolites
|
|
|